logo

OMER

Omeros·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

OMER fundamentals

Omeros (OMER) released its earnings on Nov 13, 2025: revenue was 0 (YoY 0.00%), missed estimates; EPS was -0.34 (YoY +46.88%), beat estimates.
Revenue / YoY
0
0.00%
EPS / YoY
-0.34
+46.88%
Report date
Nov 13, 2025
OMER Earnings Call Summary for Q3,2025
  • $2.1B Strategic Deal: Novo Nordisk collaboration provides $240M upfront and $100M near-term milestones.
  • Financial Turnaround: Reduced debt by 80% to $17.1M; 2027 cash flow positive.
  • YARTEMLEA Launch: FDA approval expected Q4; NTAP coverage secured.
  • Pipeline Expansion: MASP-2 antibody (Phase 2), PDE7, and T-CAT programs advancing.
EPS
Revenue

Revenue & Expenses

Key Indicators

Omeros (OMER) key financial stats and ratios, covering profitability, financial health, and leverage.
Omeros (OMER)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Omeros (OMER)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Omeros (OMER)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Omeros (OMER) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Omeros (OMER) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield